SU11248 and AG013736: current data and future trials in renal cell carcinoma.

Article Details

Citation
Copy to clipboard

Rini BI

SU11248 and AG013736: current data and future trials in renal cell carcinoma.

Clin Genitourin Cancer. 2005 Dec;4(3):175-80.

PubMed ID
16425985 [ View in PubMed
]
Abstract

Several molecular pathways are implicated in renal cell carcinoma (RCC) pathogenesis, including the von Hippel-Lindau gene inactivation leading to vascular endothelial growth factor (VEGF) and platelet derived growth factor (PDGF) expression. SU11248 and AG013736 are small-molecule inhibitors of the tyrosine kinase portion of the VEGF and PDGF receptors. Substantial clinical activity has been reported for these agents in metastatic RCC trials, leading to additional investigations in a variety of settings.

DrugBank Data that Cites this Article

Drugs